Flexion Therapeutics (NASDAQ:FLXN) Releases Earnings Results, Beats Expectations By $0.01 EPS

Flexion Therapeutics (NASDAQ:FLXN) issued its earnings results on Thursday. The specialty pharmaceutical company reported ($1.00) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.01) by $0.01, Fidelity Earnings reports. The business had revenue of $21.79 million for the quarter, compared to analyst estimates of $18.85 million. Flexion Therapeutics had a negative net margin of 368.31% and a negative return on equity of 175.29%.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Shares of Flexion Therapeutics stock traded down $0.69 during trading on Friday, reaching $16.43. The company had a trading volume of 1,132,400 shares, compared to its average volume of 622,178. The firm’s fifty day moving average is $14.85 and its 200-day moving average is $12.36. The company has a debt-to-equity ratio of 3.95, a quick ratio of 7.33 and a current ratio of 7.80. The company has a market cap of $655.05 million, a price-to-earnings ratio of -3.66 and a beta of 1.38. Flexion Therapeutics has a fifty-two week low of $8.76 and a fifty-two week high of $17.82.

A number of equities research analysts have recently issued reports on the stock. ValuEngine lowered shares of Flexion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, October 25th. BidaskClub upgraded shares of Flexion Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, November 5th. Northland Securities set a $20.00 target price on shares of Flexion Therapeutics and gave the company a “buy” rating in a research note on Tuesday, September 10th. Finally, Zacks Investment Research lowered shares of Flexion Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 8th. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Flexion Therapeutics presently has a consensus rating of “Buy” and an average target price of $23.57.

About Flexion Therapeutics

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States.

Further Reading: How do CD ladders protect against rising interest rates?

Earnings History for Flexion Therapeutics (NASDAQ:FLXN)

Leave a Reply

Your email address will not be published. Required fields are marked *